Nano-X Imaging (NASDAQ:NNOX) Receives "Sell (D-)" Rating from Weiss Ratings

Key Points

• Nano-X Imaging received a "Sell (D-)" rating from Weiss Ratings, indicating negative sentiment towards its stock.
• Despite this, other analysts have given mixed ratings, with two analysts issuing a Strong Buy and one a Buy, leading to an average price target of $8.50.
• The company's most recent quarterly results reported an EPS loss of ($0.23), missing expectations, and a revenue of $3.04 million, below the consensus estimate of $3.20 million.

Nano-X Imaging (NASDAQ:NNOX - Get Free Report)'s stock had its "sell (d-)" rating reissued by analysts at Weiss Ratings in a report issued on Saturday,Weiss Ratings reports.

A number of other research analysts have also commented on the company. D. Boral Capital reissued a "buy" rating and set a $8.00 price target on shares of Nano-X Imaging in a report on Friday, September 19th. Alliance Global Partners raised Nano-X Imaging to a "strong-buy" rating in a report on Monday, August 11th. Finally, LADENBURG THALM/SH SH raised Nano-X Imaging to a "strong-buy" rating in a research note on Monday, July 14th. Two research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $8.50.

Nano-X Imaging Trading Down 0.7%

Shares of NASDAQ NNOX opened at $4.06 on Friday. The company has a market capitalization of $234.59 million, a price-to-earnings ratio of -4.51 and a beta of 1.89. The business has a 50 day simple moving average of $3.96 and a 200-day simple moving average of $4.69. Nano-X Imaging has a twelve month low of $3.60 and a twelve month high of $11.00.

Nano-X Imaging (NASDAQ:NNOX - Get Free Report) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.23) EPS for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.08). The company had revenue of $3.04 million for the quarter, compared to the consensus estimate of $3.20 million. Nano-X Imaging had a negative return on equity of 32.09% and a negative net margin of 468.29%. As a group, equities analysts predict that Nano-X Imaging will post -0.92 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the stock. Nuveen LLC acquired a new stake in Nano-X Imaging in the 1st quarter valued at approximately $657,000. OneDigital Investment Advisors LLC increased its position in Nano-X Imaging by 16.5% in the 1st quarter. OneDigital Investment Advisors LLC now owns 32,271 shares of the company's stock worth $161,000 after buying an additional 4,570 shares during the period. ARK Investment Management LLC increased its position in Nano-X Imaging by 37.1% in the 2nd quarter. ARK Investment Management LLC now owns 315,093 shares of the company's stock worth $1,629,000 after buying an additional 85,316 shares during the period. Vident Advisory LLC bought a new position in Nano-X Imaging in the 1st quarter worth approximately $55,000. Finally, Hsbc Holdings PLC increased its position in Nano-X Imaging by 20.9% in the 1st quarter. Hsbc Holdings PLC now owns 47,984 shares of the company's stock worth $237,000 after buying an additional 8,308 shares during the period. 21.49% of the stock is owned by institutional investors.

About Nano-X Imaging

Nano-X Imaging Ltd. develops a commercial-grade tomographic imaging device with a digital X-ray source. The company provides teleradiology services and develops artificial intelligence applications to be used in real-world medical imaging applications. Its X-ray source is based on a digital micro-electro-mechanical systems semiconductor cathode.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.